Marker Therapeutics, Inc.

Tagged: TPIV

TapImmune to Present at Two Upcoming Investor Conferences

TapImmune President & CEO, Peter Hoang, will be participating in two conferences next week.

Read More

TapImmune to Participate in Two Upcoming Investor Conferences

TapImmune President & CEO, Peter Hoang, will be participating in two conferences in the upcoming weeks.

Read More

TapImmune to Present at Biotech Showcase™ 2018

TapImmune President & CEO, Peter Hoang, to present at Biotech Showcase next week.

Read More

TapImmune Inc. Presentation Now Available for On-Demand Viewing

You can now view the presentation from last Thursday’s Virtual Investor Conference call.

Read More

TapImmune Appoints Richard Kenney, M.D., F.A.C.P., as Acting Chief Medical Officer

Dr. Kenney will continue to manage the Company’s ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates.

Read More

TapImmune Inc. to Webcast, Live, at VirtualInvestorConferences.com December 7th

TapImmune President and CEO, Peter Hoang, to host live webcast on December 7th at 10:45am.

Read More

TapImmune to Present at 29th Annual Piper Jaffray Healthcare Conference

TapImmune President and CEO, Peter Hoang, will be presenting at the 29th Annual Piper Jaffray Healthcare Conference.

Read More

TapImmune to Present at World Vaccine & Immunotherapy Congress West Coast

Chairman and Strategic Advisor Glynn Wilson, Ph.D., and Senior Director of Molecular Biology & Virology Robert Florkiewicz, Ph.D., will give an oral presentation titled, “Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system,” at the World Vaccine & Immunotherapy Congress West Coast, held Thursday, November 30 – December 1, 2017, at the Loews Coronado Bay Resort in San Diego, CA.

Read More

TapImmune Provides Third Quarter 2017 Corporate and Clinical Update

Please join us for TapImmune’s third quarter 2017 corporate and clinical update today, Novmber 15th at 4:30pm ET.

Read More

TapImmune Commences Trading on the Nasdaq Capital Market

…Jacksonville, Fla. – November 8, 2016 – TapImmune, Inc., (NASDAQ: TPIV), an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today announced that its common stock has commenced trading on The Nasdaq Capital Market from the opening of market today.

Read More